Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Takeda
Massachusetts General Hospital
University of Oklahoma
Baylor College of Medicine
Gilead Sciences
K36 Therapeutics, Inc.
Alliance Foundation Trials, LLC.
M.D. Anderson Cancer Center
Fate Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Cartesian Therapeutics
University of Chicago
Baylor College of Medicine
Washington University School of Medicine
University of Arkansas
Compugen Ltd
Hospital Universitario Dr. Jose E. Gonzalez
Seagen Inc.
Cartesian Therapeutics
Servier
Taiho Oncology, Inc.
Pfizer
OriCell Therapeutics Co., Ltd.
Juno Therapeutics, a Subsidiary of Celgene
Nantes University Hospital
Fate Therapeutics
Eastern Cooperative Oncology Group
Celularity Incorporated
Genentech, Inc.
Oxford University Hospitals NHS Trust
The Affiliated People's Hospital of Ningbo University
Novartis
Novartis
Novartis
Novartis
OHSU Knight Cancer Institute
Case Comprehensive Cancer Center
Celularity Incorporated
Herlev Hospital
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Celgene
Abramson Cancer Center at Penn Medicine
University of Wisconsin, Madison
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University College, London
University of Maryland, Baltimore
Mayo Clinic